An open, comparative pilot study of thiamphenicol glycinate hydrochloride vs clarithromycin in the treatment of acute lower respiratory tract infections due to Chlamydia pneumoniae.

Abstract	The aim of this study was to evaluate the efficacy and tolerability of thiamphenicol glycinate hydrochloride (TGH) i.m. versus clarithromycin in acute lower respiratory infections due to Chlamydia pneumonia. 113 patients with suspected pneumonia were screened. 40 patients with IgM and/or IgA titers > or = 1:16 and/or IgG titers > or = 1:512 were assigned to 10 days of treatment with TGH 1500 mg daily or clarithromycin 1000 mg daily. 34 patients were considered a clinical success. 33 patients were a radiological success. 22 patients showed a decrease in IgG values. 3 patients had an increase in IgG values. Blood/urine values presented no clinically significant variations. Clinical efficacy was similar in both treatment groups. These are the first results confirming in vivo the recent in vitro evidence that TGH is effective against acute lower respiratory tract infections due to C. pneumoniae, thus representing an alternative therapy to clarithromycin.
Authors	T Todisco, A Eslami, S Baglioni, C Todisco
Journal	Journal of chemotherapy (Florence, Italy) (J Chemother) Vol. 14 Issue 3 Pg. 265-71 (Jun 2002) ISSN: 1120-009X [Print] England
PMID	12120881 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)
Chemical References	Anti-Bacterial Agents Immunoglobulins Thiamphenicol Clarithromycin thiamphenicol glycinate
Topics	Administration, Oral Adult Aged Anti-Bacterial Agents (administration & dosage, therapeutic use) Chlamydophila Infections (diagnostic imaging, drug therapy) Chlamydophila pneumoniae Clarithromycin (administration & dosage, therapeutic use) Drug Administration Schedule Female Humans Immunoglobulins (blood) Male Middle Aged Pilot Projects Pneumonia, Bacterial (diagnostic imaging, drug therapy) Radiography Thiamphenicol (administration & dosage, analogs & derivatives, therapeutic use) Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!